Company intelligence / Profile preview

Paragard

Trumbull, Connecticut, United States

Ownership: Private
Development stage: Other

Overview

Paragard is a medical device brand and business unit that specializes in non-hormonal intrauterine contraception. The company's flagship product, the Paragard T 380A, is the only FDA-approved copper intrauterine device (IUD) available in the United States, providing highly effective pregnancy prevention for up to 10 years. In 2017, the Paragard business was acquired from Teva Pharmaceutical Industries by CooperSurgical, a subsidiary of CooperCompanies, for $1.1 billion. Paragard is positioned as a leading option for women seeking long-term, reversible, and hormone-free birth control. The business operates with dedicated manufacturing and commercial infrastructure to support its widespread use in women's healthcare.

Therapeutic areas: Women's Health
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Paragard.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paragard.

Explore the full profile